ZINIO logo
ESPLORALA MIA LIBRERIA
Scienza
New Scientist International Edition

New Scientist International Edition 21-Nov-20

New Scientist covers the latest developments in science and technology that will impact your world. New Scientist employs and commissions the best writers in their fields from all over the world. Our editorial team provide cutting-edge news, award-winning features and reports, written in concise and clear language that puts discoveries and advances in the context of everyday life today and in the future.

Leggi di più
Paese:
United Kingdom
Lingua:
English
Editore:
New Scientist Ltd
Frequenza:
Weekly
COMPRA NUMERO
6,88 €(VAT inclusa)
ABBONATI
128,92 €(VAT inclusa)
51 Numeri

in questo numero

1 minuti
elsewhere on new scientist

Academy The biggest mysteries of the cosmos The first course from New Scientist Academy is now on sale. If you are fascinated by the the universe, this expert-led introductory course is for you. newscientist.com/courses Podcast Weekly In this week’s podcast, the team discusses news of a vaccine for covid-19, examines the origin of animals and takes a deep dive into the thorny debate about human population. newscientist.com/podcasts Newsletter Launchpad Our free weekly newsletter delivers all the space news you could ask for to your inbox. The latest edition looks at the mystery of fast radio bursts. newscientist.com/sign-up/launchpad Online Covid-19 daily briefing All the most important coronavirus coverage in news, features and interviews. Updated at 6pm GMT. newscientist.com/coronavirus-latest…

2 minuti
a note from our news editor

AS A New Scientist reader, you probably know that the study of human origins is one of the most exciting fields around at the moment. In the past decade, we have seen a complete revolution in our understanding of how we evolved, and it seems as if not a week goes by without a new fossil or discovery that rewrites the history books. That is why we are delighted to be launching a free monthly newsletter, Our Human Story, to chronicle these extraordinary finds. It will be written by Michael Marshall, a former New Scientist staff writer and regular freelancer who will no doubt be a familiar name from these pages. The first edition, which will be going out on 24 November, is full of fascinating material. Michael will expand on his…

2 minuti
the end is in sight

WHAT a difference a week makes. In about that time, we have gone from having little more than hope that a coronavirus vaccine would work, to having promising results from not one but three trials. As last week’s issue went to press, we had just heard the news that a vaccine candidate in late-stage human trials seems to be safe and effective – at least according to interim findings. That was the vaccine from US firm Pfizer and its German partner BioNTech. Then came the results – albeit in a smaller sample – from Russia’s Sputnik V vaccine. And on Monday, US firm Moderna chimed in with interim findings for its vaccine (see page 7), the most promising of all, which encouragingly seems to have an effect even for older people. These…

3 minuti
vaccine trial hat-trick

IMPRESSIVE early trial results for another coronavirus vaccine appear to trump those released just a week ago by Pfizer and BioNTech, and ones from a Russian trial. The latest results, for Moderna’s mRNA-1273 vaccine, suggest that it is 95 per cent effective and works in those who need protecting the most – people aged over 65 – the US-based company announced on 16 November. The vaccine can also be stored in a normal freezer or fridge, which would help with distributing it. If the Moderna and Pfizer vaccines work as well as their results imply, the prospects look good for other coronavirus vaccines that act in the same way, several of which are already undergoing human trials. Such vaccines are desperately needed: about 55 million covid-19 cases have now been reported globally,…

13 minuti
vaccines: hope vs reality

IT IS the ultimate exit strategy from covid-19. A safe and effective vaccine is of “critical importance to world health”, the World Health Organization (WHO) has said. Vaccine developers are working flat out to make good on that. Last week, the US pharmaceutical giant Pfizer and its German partner BioNTech announced positive-looking results from their ongoing phase III trial, the last stage of testing whether a potential vaccine is safe and effective. The interim results showed a headline success rate of 90 per cent, meaning that nine out of 10 trial participants who caught the new coronavirus had received a placebo rather than the vaccine. “How long will immunity last? The desired answer is ‘forever’, but realistically a year would be positive” The news got some people very excited indeed. Asked on BBC…

1 minuti
how the pfizer/biontech phase iii trial works

More than 43,500 people are recruited to the trial Around half are given a vaccine, half get a placebo. Neither participants nor researchers know who is in which group When participants report mild symptoms like a cough or fever they are tested for the coronavirus Once a certain number of people are confirmed as having had covid-19, called a “checkpoint”, the results are “unblinded” to reveal whether these positive cases had been given a vaccine or a placebo So far, of 94 covid-19 cases, 90 per cent were among those in the placebo group The trial will end when there have been 164 confirmed infections, the final checkpoint…